References

  1. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer.

    Nat Rev Cancer 2007 , 7:441-53. PubMed Abstract | Publisher Full Text OpenURL

  2. Hagemeijer A, de Klein A, Godde-Salz E, Turc-Carel C, Smit EM, van Agthoven AJ, Grosveld GC: Translocation of c-abl to "masked" Ph in chronic myeloid leukemia.

    Cancer Genet Cytogenet 1985 , 18:95-104. PubMed Abstract | Publisher Full Text OpenURL

  3. Morris CM, Reeve AE, Fitzgerald PH, Hollings PE, Beard ME, Heaton DC: Genomic diversity correlates with clinical variation in Ph'-negative chronic myeloid leukaemia.

    Nature 1986 , 320:281-3. PubMed Abstract | Publisher Full Text OpenURL

  4. Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Plas D, Grosveld G: Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia.

    Genes Chromosomes Cancer 1993 , 8:237-45. PubMed Abstract | Publisher Full Text OpenURL

  5. Nacheva E, Holloway T, Brown K, Bloxham D, Green AR: Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22.

    Br J Haematol 1994 , 87:409-12. PubMed Abstract | Publisher Full Text OpenURL

  6. Morris CM, Heisterkamp N, Kennedy MA, Fitzgerald PH, Groffen J: Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22.

    Blood 1990 , 76:1812-8. PubMed Abstract | Publisher Full Text OpenURL

  7. Valle L, Fernandez V, Perez-Pons C, Sanchez FG, Benitez J, Urioste M: Generation of the BCR/ABL fusion gene in a Philadelphia chromosome-negative chronic myeloid leukaemia: insertion of 5.6 Mb of 9q34 into the BCR region of chromosome 22.

    Hematol Oncol 2006 , 24:86-8. PubMed Abstract | Publisher Full Text OpenURL

  8. Zagaria A, Anelli L, Albano F, Vicari L, Schiavone EM, Annunziata M, Pane F, Liso V, Rocchi M, Specchia G: Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.

    Cancer Genet Cytogenet 2006 , 167:97-102. PubMed Abstract | Publisher Full Text OpenURL

  9. Storlazzi CT, Anelli L, Surace C, Lonoce A, Zagaria A, Nanni M, Curzi P, Rocchi M: Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia.

    Cancer Genet Cytogenet 2002 , 136:141-5. PubMed Abstract | Publisher Full Text OpenURL

  10. Todoric-Zivanovic B, Marisavljevic D, Surace C, Cemerikic V, Markovic O, Krtolica K, Tatomirovic Z, Cikota B, Magic Z, Rocchi M: A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1).

    Cancer Genet Cytogenet 2006 , 166:180-5. PubMed Abstract | Publisher Full Text OpenURL

  11. Kuriyama K, Gale RP, Tomonaga M, Ikeda S, Yao E, Klisak I, Whelan K, Yakir H, Ichimaru M, Sparkes RS, Dreazen O: CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia.

    Blood 1989 , 74:1381-7. PubMed Abstract | Publisher Full Text OpenURL

  12. Gribble SM, Reid AG, Roberts I, Grace C, Green AR, Nacheva EP: Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation.

    Genes Chromosomes Cancer 2003 , 37:346-58. PubMed Abstract | Publisher Full Text OpenURL

  13. De Melo VA, Milojkovic D, Marin D, Apperley JF, Nacheva EP, Reid AG: Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

    Cancer Genet Cytogenet 2008 , 182:111-5. PubMed Abstract | Publisher Full Text OpenURL

  14. UCSC Human Genome Browser Gateway [http://genome.ucsc.edu]

  15. Human 32K BAC Re-Array [http://bacpac.chori.org/genomicRearrays.php]

  16. Spectral Genomics [http://www.spectralgenomics.com]

  17. Agilent [http://www.agilent.com]

  18. Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP: Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.

    Genes Chromosomes Cancer 2007 , 46:1039-50. PubMed Abstract | Publisher Full Text OpenURL

  19. Molecular Cytogenetics of Haematological Disorders [http://www.ucl.ac.uk/leukemia-cytogenetics]

  20. Guerrero C, Fernandez-Medarde A, Rojas JM, Font de Mora J, Esteban LM, Santos E: Transformation suppressor activity of C3G is independent of its CDC25-homology domain.

    Oncogene 1998 , 16:613-24. PubMed Abstract | Publisher Full Text OpenURL

  21. Guerrero C, Martin-Encabo S, Fernandez-Medarde A, Santos E: C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth.

    Oncogene 2004 , 23:4885-93. PubMed Abstract | Publisher Full Text OpenURL

  22. Cho YJ, Hemmeryckx B, Groffen J, Heisterkamp N: Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.

    Biochem Biophys Res Commun 2005 , 333:1276-83. PubMed Abstract | Publisher Full Text OpenURL

  23. Ahuja HS, Szanto A, Nagy L, Davies PJ: The retinoid × receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death.

    J Biol Regul Homeost Agents 2003 , 17:29-45. PubMed Abstract OpenURL

  24. Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch T, Strobl H: Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors.

    Blood 2007 , 109:971-9. PubMed Abstract | Publisher Full Text OpenURL

  25. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, Berthier C, Kamashev D, Zhou J, Vitoux D, Lavau C, de The H: RXR is an essential component of the oncogenic PML/RARA complex in vivo.

    Cancer Cell 2007 , 12:23-35. PubMed Abstract | Publisher Full Text OpenURL

  26. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, So CW: Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation.

    Cancer Cell 2007 , 12:36-51. PubMed Abstract | Publisher Full Text OpenURL

  27. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

    Blood 2000 , 95:738-43. PubMed Abstract | Publisher Full Text OpenURL

  28. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.

    Blood 2001 , 98:1732-8. PubMed Abstract | Publisher Full Text OpenURL

  29. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

    Blood 2003 , 102:2205-12. PubMed Abstract | Publisher Full Text OpenURL

  30. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

    Blood 2005 , 105:2281-6. PubMed Abstract | Publisher Full Text OpenURL

  31. Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC: Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

    Blood 2007 , 110:1283-90. PubMed Abstract | Publisher Full Text OpenURL

  32. Batista DA, Hawkins A, Murphy KM, Griffin CA: BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present.

    Cancer Genet Cytogenet 2005 , 163:164-7. PubMed Abstract | Publisher Full Text OpenURL

  33. Costa D, Espinet B, Queralt R, Carrio A, Sole F, Colomer D, Cervantes F, Hernandez JA, Besses C, Campo E: Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia.

    Cancer Genet Cytogenet 2003 , 141:114-9. PubMed Abstract | Publisher Full Text OpenURL

  34. Dufva IH, Karle H, Brondum-Nielsen K, Andersen MK, Madsen HO, Johnsen HE: Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation–durable complete remission following imatinib therapy.

    Leukemia 2005 , 19:671-3. PubMed Abstract | Publisher Full Text OpenURL

  35. Fugazza G, Garuti A, Marchelli S, Miglino M, Bruzzone R, Gatti AM, Castello S, Sessarego M: Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia.

    Cancer Genet Cytogenet 2005 , 163:173-5. PubMed Abstract | Publisher Full Text OpenURL